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post-treatment with tocotrienols in a rat model of local heart 
irradiation. 
Materials and Methods: Male Sprague-Dawley rats received localized 
image-guided X-ray irradiation of the heart with a single dose of 21 
Gy. Groups of animals received a tocotrienol-enriched oral 
formulation 24 hours before irradiation, or in combination with 
pentoxifylline (PTX) starting 3 months after irradiation. At 6 months 
after irradiation, cardiac function and tissue structure were measured 
with echocardiography and histopathology. At time points from 6 
hours to 9 months after irradiation, left ventricular molecular changes 
were examined with real-time PCR and Western-Blots. In addition, 
mitochondria were isolated from left ventricular tissue samples to 
examine mitochondrial membrane potential, mitochondrial transition 
pore activity, and respiration. 
Results: Local heart irradiation caused long term changes in cardiac 
function and structure, coinciding with changes in the expression of 
mediators of the epidermal growth factor receptor (EGFR) pathway, 
and changes in mitochondrial membrane properties and respiration. 
Pretreatment of rats with tocotrienols prevented these effects of 
radiation. Unexpectedly, the late treatment with PTX caused 
bradycardia and arrhythmia in irradiated animals. This adverse event 
was not prevented when tocotrienols were added to the PTX 
treatment. On the other hand, addition of tocotrienols reduced 
cardiac numbers of macrophages and mast cells and enhanced left 
ventricular gene expression of the EGFR mediator neuregulin-1.  
Conclusions: These studies suggest that tocotrienols may be potent 
protectors against cardiac radiation toxicity. Further studies should 
address the effects of tocotrienols when administered after 
irradiation, alone or in combination with other potential mitigators.  
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Purpose/Objective: The radiation dose that can be delivered to 
thoracic tumors is limited by the risk of radiation-induced lung 
toxicity (RILT). ACE-inhibition has been shown to ameliorate RILT in 
rats although the exact mechanism is not elucidated (1). Recently, we 
found that pulmonary vascular remodeling plays an important role in 
the development of RILT in rats resulting in pulmonary hypertension, 
right ventricle hypertrophy and eventually to cardio-pulmonary 
dysfunction (2). We hypothesized that the protective effect of ACE-
inhibition might be due to reduced vascular remodeling and 
pulmonary hypertension. Therefore, in this study we investigated if 
ACE-inhibition ameliorates early radiation-induced cardio-pulmonary 
dysfunction by protection of pulmonary vascular remodeling. 
Materials and Methods: To elucidate the exact protective mechanism 
of ACE-inhibition on early radiation-induced cardio-pulmonary 
function loss rats' lungs, heart or heart and lung were irradiated to 20 
Gy using high-precision proton beams. Captopril was administered in 
the drinking water immediately after irradiation. Cardio-pulmonary 
performance was assessed in the irradiated rats (± captopril) using 
biweekly breathing rate measurements. At 8 weeks post-irradiation, 
when early radiation-induced cardio-pulmonary dysfunction peaks (2), 
left- and right-sided cardiac hemodynamics were measured, CT scans 
and histopathology were analyzed. 
Results: At 8 weeks post-irradiation breathing rate measurements 
showed that captopril significantly improved the rats' cardiac/ 
pulmonary function, but only in the rats where the heart was included 
in the radiation field. Consistently, CT scans showed improvement of 
pulmonary density/structure by captopril only in the heart-irradiated 
groups. 
This protective effect could not be explained by protection of the 
pulmonary vasculature or pulmonary artery pressure changes, which 
were equally damaged with or without captopril. Interestingly, 
besides decreasing the presence of pleural and pericardial effusion, 
left ventricle hemodynamic measurements showed better cardiac 
function parameters in the captopril treated rats. Next to that, 
captopril treatment reduced perivascular fibrosis in the irradiated 
hearts.  
Conclusions: Captopril ameliorates early radiation-induced cardio-
pulmonary dysfunction by reducing acute heart damage and 
consequentially reduces excess RILT caused by inclusion of the heart 
in the irradiation field (3). ACE-inhibition may be a promising strategy 
to reduce early cardio-pulmonary complications induced by 
radiotherapy to the thoracic area in patients receiving a dose to the 
heart.  
 (1) Ghosh et al. Int J Radiat Oncol Biol Phys 2009 
(2) Ghobadi et al. Thorax 2011 
(3) van Luijk et al. Cancer Res 2005 
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Purpose/Objective: This study describes a new treatment verification 
system, based on electronic portal imaging device (EPID) images, for 
HDR brachytherapy. The phantom study incorporates verification of 
both source position and dose as the brachytherapy treatment plan is 
delivered, identifying the potential for real time identification of 
incorrect dose to patients. 
Materials and Methods: An a-Si EPID (IAS11-19, Varian Medical 
Systems,Palo Alto, CA, USA) was used for all measurements. Response 
characteristics of the EPID were determined for use with an Ir-192 
HDR brachytherapy source, including linearity, reproducibility, 
variation in exposure time, image acquisition time,photon energy 
dependence and source position determination in three dimensions.A 
treatment plan was delivered to the phantom and for each dwell 
position in the delivered plan, planar EPID dose distributions were 
compared with the TPS calculated at the same plane. 
Results: Analysis of the EPID images containing the source response 
distribution, yielded the location of the source to better than ± 1mm 
for coordinates parallel to the plane of the EPID at source-to-detector 
distances up to 200mm. The source distance from the EPID surface 
could be determined to within ± 1.5 mm. The comparison of TPS and 
measured dose at a plane 100mm from the brachytherapy source 
agreed to within ± 2% for a 100 x 100 mm region of the EPID plane 
centered at the source (x,y)coordinates, and agreed to within ± 7% 
across the entire EPID panel (300x400mm). Delivery of an erroneous 
treatment plan with missing or incorrectly located dwell positions was 
easily identifiable with this system. 
Conclusions: This is the first system, to our knowledge, providing a 
check of both source position and dwell time during dose delivery. 
The EPID images are sensitive enough to reveal clinically relevant 
source position and dwell time errors. We have established a proof-of-
principle that an EPID can be used for treatment verification in HDR 
brachytherapy.  
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Purpose/Objective: To correlate the dose-volume parameters D90 (Gy) 
and V100 (%) (i.e. minimum dose to 90% of the prostate volume and 
volume that received 100% of the prescribed iso-dose, respectively) 
with biochemical control in patients with advanced prostate cancer 
treated with external beam radiotherapy (EBRT) followed by a boost 
of high-dose rate brachytherapy (HDR-BT). 
Materials and Methods: 108 patients, participating in a randomised 
trial of EBRT± HDR-BT, received EBRT to 35.75 Gy in 13 fractions 
followed by HDR-BT of 2 x 8.5 Gy. Kaplan-Meier freedom-from-
biochemical relapse (FFbR) rates were obtained by stratifying the data 
by those whose D90 and V100 were at or above and below the first (Q1), 
second (Q2) and third (Q3) quartile. Differences between groups were 
compared using the log-rank test. Univariate and multivariate hazard 
ratios for D90 and V100 and other co-variates (prostate specific antigen 
(PSA), androgen deprivation therapy (ADT)) were obtained using Cox's 
proportional hazard model. 
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Results: Differences in demographic and prognostic features (age, T 
stage, Gleason score, pre-treatment PSA, ADT) were not significant. 
 
 
Figure 1 compares time-incidence curves generated using the 1st, 2nd 
and 3rd quartile D90 levels as cut-off points. A progressive, dose 
related increase in biochemical control of disease is seen with 
increasing D90. FFbR was significantly higher in patients whose D90 was 
≥ the median value compared to D90 < median (p = 0·006). Similar 
findings were seen for V100. 
 
Table 1 shows 5-year FFbR rates for D90 and V100. In multivariate 
analysis D90, (p = 0.004), V100 (p = 0.0004), PSA (p = 0.03) and ADT (p = 
0.01) were significant covariates for risk of relapse. 
Conclusions: Dichotomising the data using 6 levels of response (above 
and below Q1, Q2 and Q3) showed a clear dose response with 
progressive and continuous improvement in biochemical control of 
disease across the entire dose (and volume) range. The data show that 
a minimum D90 of 108% of the prescribed dose should be the target to 
achieve. Implant quality is an important predictor of outcome after 
HDR brachytherapy. 
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Purpose/Objective: This retrospective study was performed to 
compare different boost techniques after breast conserving therapy 
(breast conserving surgery followed by whole breast irradiation) in 
terms of local and loco-regional recurrences. 
Materials and Methods: From 2000 to 2005, 1576 patients were 
treated with breast conserving therapy for in situ or invasive breast 
cancer. An electron boost (EB) was performed for a superficial boost-
volume (less than 29 mm under the epidermis), in all other cases a 
brachytherapy boost (BTB) was proposed. When patients refused a 
BTB or a BTB was not possible because of technical reasons, a photon 
boost (PB) was given. 75.8% (1195) of the patients received an EB 
after whole breast irradiation (WBI). 16.3% (257) of the patients were 
given a BTB (either with LDR or PDR) and only 5.6% (89) of the 
patients had a PB. The primary endpoints were local and loco-regional 
recurrences. Secondary endpoints were metastasis-free survival and 
overall survival, taking into account patient and treatment 
characteristics. 
Results: The median follow-up for all patients was 8.9 years in 
invasive cancer and 8.8 years in in situ cancer. Of the 1381 invasive 
breast cancer patients, we observed 35 (2.5%) local and loco-regional 
recurrences. Five- and 10-years relapse-free survival rates were 98.8% 
and 96.9%. Five- and 10-years overall survival rates were 95.1% and 
86.2%. We found no significant differences between the three boost 
techniques with respect to relapse risk or overall survival. The 
metastasis-free survival was longer in the EB group (90.7% at 10 years) 
and the BTB group (87.3% at 10 years) than in the PB group (82.7% at 
10 years). This difference was not significant anymore after correction 
for tumor stage (pT) (p=0.09) or lymph node stage (pN) (p=0.1). Of the 
195 patients with an in situ carcinoma, we found one local and one 
loco-regional recurrence. Five- and 10-years overall survival rates in 
this group were 99.5% and 93.8%. 
Conclusions: In women treated with breast conserving therapy 
followed by a boost irradiation to the tumour bed, the local and loco-
regional recurrences at 10 years in our institution are very low for 
invasive as well as for in situ breast cancer. No difference in 
recurrence was observed comparing the three different boost 
techniques.  
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Purpose/Objective: There is currently limited evidence for HR CTV 
dose planning aims in locally advanced cervical cancer. This study 
analyses dose-response for local control in image-guided adaptive 
brachytherapy (IGABT). 
Materials and Methods: RetroEMBRACE is a retrospective study with 
796 locally advanced cervical cancer patients treated in 12 institu-
tions by IGABT using GEC ESTRO guidelines. In 592 patients data was 
available on local status, HR CTV dose and volumes. FIGO stage distri-
bution was IB (19%), IIA (7%), IIB (50%), IIIA (3%), IIIB (18%), IV (3%). 
IGABT was combined with 45-50Gy whole pelvis EBRT and weekly 
cisplatinum (76%). IGABT was based on MRI (81%) or CT (19%), and was 
administered as high dose rate (HDR) (60%) or pulsed dose rate (PDR) 
(40%). Patient groups were formed according to 1) tumour width at 
diagnosis (cut-point 50mm), 2) HR CTV volume (cut-point 35cc), 3) 
stage (IB, IIA-IIB, III-IV), 4) histology (SQ versus AC+AdSq), and 5) dose 
rate (HDR versus PDR). HR CTV D90 dose-response for local control 
was evaluated in each sub-group by logit analysis. Dose for 90% and 
95% local control (TCD90 and TCD95) was determined. 
Results: At a median follow up of 31 (3-150) months, 48 local failures 
have been observed. HR CTV volume was 35cc±24cc and HR CTV D90 
87Gy±14Gy. A significant (p<0.05) dependence of local control on D90 
for HR CTV was found in the entire patient population (Figure 1) and 
in all subgroups except PDR (p=0.07) (Table 1). Logit analysis was not 
performed in stage IB due to limited number of events: 2/32 (6%) and 
0/83 (0%) local failures above and below 80Gy, respectively. In the 
'favourable' subgroups 'width<50mm', 'HR CTV volume<35cc' and 'stage 
IIB', local control >95% was seen for HR CTV D90 larger than 87Gy, 
85Gy and 93Gy, respectively. In the 'unfavourable' subgroups 
'width>50mm', 'HR CTV volume>35cc', 'IIIA, IIIB, IVA', local control 
rates of >90% was seen for HR CTV D90 larger than 85Gy, 89Gy and 
93Gy, respectively. There was no significant difference between dose 
response for HDR and PDR (p=0.113). There was a significant differ-
ence between SQ and AC+AdSq (p=0.02) with AC+AdSq being less 
favourable, in particular for lower doses. 
 
